ABIONYX Pharma has an ambitious vision in ophthalmology: to transform the management of inflammatory eye diseases by addressing their root causes rather than just their symptoms. With ABNX-100, the ophthalmic version of CER-001, the company is introducing a radically new approach based on the unique properties of recombinant apolipoprotein A-I.
Uveitis, which accounts for nearly 30% of ophthalmology consultations, is a major public health issue. This complex, often chronic and recurrent condition can lead to irreversible vision loss despite current treatments, which are mainly based on corticosteroids and immunosuppressants. In this context, ABIONYX aims to offer an innovative systemic solution capable of restoring the physiological balance of the eye.
ABNX-100 acts at the intersection of two key mechanisms: lipid regulation and inflammation modulation. By promoting the resolution of inflammatory processes and tissue repair, this molecule paves the way for regenerative medicine in ophthalmology, with the goal of sustainably improving visual function.
Building on the expertise acquired with CER-001, ABIONYX Pharma intends to position ABNX-100 as a benchmark in the treatment of uveitis, addressing a largely unmet medical need. This strategy illustrates the group's desire to establish itself as a disruptive player, capable of redefining therapeutic standards and creating significant value for both patients and healthcare partners.